Treatment options for graft-versus-host disease

Bibliography

• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945-56
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18(4):295-304
   PubMed Web of Science ®Google Scholar
• Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 2013;19(5):767-76
   PubMed Web of Science ®Google Scholar
• Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981;11(1):1-8
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983;46(3):125-32
   PubMedGoogle Scholar
• Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993;56(3):577-80
   PubMedGoogle Scholar
• Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009;113(13):2888-94
   PubMed Web of Science ®Google Scholar
• Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998;92(7):2288-93
   PubMed Web of Science ®Google Scholar
• Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109(10):4119-26
   PubMed Web of Science ®Google Scholar
• Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000;6(4A):441-7
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Milone G, et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010;45(2):385-91
   PubMed Web of Science ®Google Scholar
• Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004;104(5):1559-64
   PubMed Web of Science ®Google Scholar
• Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11(9):680-7
   PubMed Web of Science ®Google Scholar
• Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008;111(4):2470-5
   PubMed Web of Science ®Google Scholar
• Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114(3):511-17
   PubMed Web of Science ®Google Scholar
• Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18(8):1150-63
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001;98(7):2052-8
   PubMed Web of Science ®Google Scholar
• Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007;109(6):2657-62
   PubMed Web of Science ®Google Scholar
• Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004;33(1):131-2
   PubMed Web of Science ®Google Scholar
• Wandroo F, Auguston B, Cook M, et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 2004;34(3):285-7
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Lovisone E, et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biol Blood Marrow Transplant 2005;11(9):734-6
   PubMed Web of Science ®Google Scholar
• Schnitzler M, Hasskarl J, Egger M, et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15(8):910-18
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14(1):10-15
   PubMed Web of Science ®Google Scholar
• Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(4):1224-6
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Georges GE, Storb R. Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model. Biol Blood Marrow Transplant 2006;12(9):899-904
   PubMed Web of Science ®Google Scholar
• Faraci M, Lanino E, Morreale G, et al. Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD. Bone Marrow Transplant 2011;46(1):159-60
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82(1):45-52
   PubMed Web of Science ®Google Scholar
• Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000;96(7):2426-31
   PubMed Web of Science ®Google Scholar
• Rubegni P, Feci L, Poggiali S, et al. Extracorporeal photopheresis: a useful therapy for patients with steroids refractory acute graft versus host disease but not for the prevention of the chronic form. Br J Dermatol 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008;42(9):609-17
   PubMed Web of Science ®Google Scholar
• Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 2007;29(10):678-87
   PubMed Web of Science ®Google Scholar
• Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91(3):405-8
   PubMed Web of Science ®Google Scholar
• Jagasia M, Greinix H, Robin M, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant 2013;19(7):1129-33
   PubMed Web of Science ®Google Scholar
• Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72(12):1924-9
   PubMed Web of Science ®Google Scholar
• Hoda D, Pidala J, Salgado-Vila N, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010;45(8):1347-51
   PubMed Web of Science ®Google Scholar
• Rosenthal J, Pawlowska A, Bolotin E, et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer 2011;57(1):142-6
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371(9624):1579-86
   PubMed Web of Science ®Google Scholar
• Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81(10):1390-7
   PubMed Web of Science ®Google Scholar
• von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009;43(3):245-51
   PubMed Web of Science ®Google Scholar
• Fang B, Song Y, Liao L, et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007;39(10):3358-62
   PubMed Web of Science ®Google Scholar
• Ringden O, Erkers T, Nava S, et al. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 2013;31(3):592-601
   PubMed Web of Science ®Google Scholar
• Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998;22(1):61-5
   PubMed Web of Science ®Google Scholar
• Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009;44(11):739-48
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73(1):56-61
   PubMed Web of Science ®Google Scholar
• Takami A, Mochizuki K, Okumura H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006;83(1):80-5
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Perkins J, et al. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010;45(5):919-24
   PubMed Web of Science ®Google Scholar
• Onishi C, Ohashi K, Sawada T, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol 2010;91(3):464-70
   PubMed Web of Science ®Google Scholar
• Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002;30(5):287-95
   PubMed Web of Science ®Google Scholar
• Herve P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990;75(4):1017-23
   PubMed Web of Science ®Google Scholar
• Cuthbert RJ, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992;10(5):451-5
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Stefanic M, Sandherr M, et al. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563). Transplant Proc 1994;26(6):3114-16
   PubMed Web of Science ®Google Scholar
• Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84(4):1320-7
   PubMed Web of Science ®Google Scholar
• Funke VA, de Medeiros CR, Setubal DC, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006;37(10):961-5
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30(12):899-903
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005;130(4):568-74
   PubMed Web of Science ®Google Scholar
• Wang JZ, Liu KY, Xu LP, et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc 2011;43(5):1928-33
   PubMed Web of Science ®Google Scholar
• Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35(10):1003-10
   PubMed Web of Science ®Google Scholar
• Hsu B, May R, Carrum G, et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001;28(10):945-50
   PubMed Web of Science ®Google Scholar
• Dugan MJ, DeFor TE, Steinbuch M, et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997;75(1-2):41-6
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002;8(1):40-6
   PubMed Web of Science ®Google Scholar
• Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992;10(1):77-82
   PubMed Web of Science ®Google Scholar
• Graziani F, Van Lint MT, Dominietto A, et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002;87(9):973-8
   PubMed Web of Science ®Google Scholar
• Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006;107(10):4177-81
   PubMed Web of Science ®Google Scholar
• Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8(3):155-60
   PubMed Web of Science ®Google Scholar
• McCaul KG, Nevill TJ, Barnett MJ, et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000;9(3):367-74
   PubMedGoogle Scholar
• Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001;27(10):1059-64
   PubMed Web of Science ®Google Scholar
• Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001;15(3):147-53
   PubMed Web of Science ®Google Scholar
• Ballesteros M, Ferra C, Serrano D, et al. Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. Am J Hematol 2008;83(10):824-5
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9(9):1144-50
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196(3):389-99
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011;23(5):679-84
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Edinger M. Polyclonal expansion of human CD4(+)CD25(+) regulatory T cells. Methods Mol Biol 2011;677:15-30
   PubMedGoogle Scholar
• Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008;134-41
   PubMedGoogle Scholar
• Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010;16(12):1611-28
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72(2):555-61
   PubMed Web of Science ®Google Scholar
• Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100(1):48-51
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72(2):546-54
   PubMed Web of Science ®Google Scholar
• Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009;113(21):5074-82
   PubMed Web of Science ®Google Scholar
• Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17(1):1-17
   PubMed Web of Science ®Google Scholar
• Shapira MY, Abdul-Hai A, Resnick IB, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009;43(4):339-43
   PubMed Web of Science ®Google Scholar
• Toor AA, Stiff PJ, Nickoloff BJ, et al. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat 2007;18(1):13-18
   PubMed Web of Science ®Google Scholar
• Nikiforow S, Kim HT, Bindra B, et al. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2013;19(5):804-11
   PubMed Web of Science ®Google Scholar
• Moreira V, De Medeiros BC, Bonfim CM, et al. Methemoglobinemia secondary to clofazimine treatment for chronic graft-versus-host disease. Blood 1998;92(12):4872-3
   PubMed Web of Science ®Google Scholar
• Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis–results of a crossover randomized study. Biol Blood Marrow Transplant 2011;17(12):1775-82
   PubMed Web of Science ®Google Scholar
• Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112(7):2667-74
   PubMed Web of Science ®Google Scholar
• Dignan FL, Greenblatt D, Cox M, et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012;47(6):824-30
   PubMed Web of Science ®Google Scholar
• Del Fante C, Scudeller L, Viarengo G, et al. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. Transfusion 2012;52(9):2007-15
   PubMed Web of Science ®Google Scholar
• Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002;73(4):665-7
   PubMed Web of Science ®Google Scholar
• Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6(3A):327-34
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005;130(3):409-17
   PubMed Web of Science ®Google Scholar
• Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005;11(1):47-55
   PubMed Web of Science ®Google Scholar
• Jurado M, Vallejo C, Perez-Simon JA, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13(6):701-6
   PubMed Web of Science ®Google Scholar
• Magro L, Catteau B, Coiteux V, et al. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008;42(11):757-60
   PubMed Web of Science ®Google Scholar
• Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009;114(3):719-22
   PubMed Web of Science ®Google Scholar
• Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12(7):789-91
   PubMed Web of Science ®Google Scholar
• Moreno-Romero JA, Fernandez-Aviles F, Carreras E, et al. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008;144(9):1106-9
   PubMedGoogle Scholar
• Stadler M, Ahlborn R, Kamal H, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009;114(17):3718-19; author reply 19-20
   PubMed Web of Science ®Google Scholar
• Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009;114(3):709-18
   PubMed Web of Science ®Google Scholar
• de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012;120(25):5089-90
   PubMed Web of Science ®Google Scholar
• Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-66
   PubMed Web of Science ®Google Scholar
• Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010;45(12):1732-40
   PubMed Web of Science ®Google Scholar
• Inagaki J, Nagatoshi Y, Hatano M, et al. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant 2008;41(6):571-7
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Mohty M, Faucher C, et al. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006;91(10):1438-40
   PubMed Web of Science ®Google Scholar
• Huang XJ, Jiang Q, Chen H, et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;36(4):343-8
   PubMed Web of Science ®Google Scholar
• Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005;36(4):337-41
   PubMed Web of Science ®Google Scholar
• Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000;25(10):1067-71
   PubMed Web of Science ®Google Scholar
• Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003;25(7):584-8
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007;25(27):4255-61
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood 2009;114(20):4354-60
   PubMed Web of Science ®Google Scholar
• Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999;93(1):66-70
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Thomas P, Penovici M, et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol 2008;18(6):667-70
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15(9):1005-13
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108(2):756-62
   PubMed Web of Science ®Google Scholar
• van Dorp S, Resemann H, te Boome L, et al. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. Haematologica 2011;96(9):1380-4
   PubMed Web of Science ®Google Scholar
• Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7(9):495-502
   PubMed Web of Science ®Google Scholar
• Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326(16):1055-8
   PubMed Web of Science ®Google Scholar
• Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26(8):865-9
   PubMed Web of Science ®Google Scholar
• Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86(9):3604-9
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003;32(2):165-70
   PubMed Web of Science ®Google Scholar
• Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990;49(3):657-8
   PubMed Web of Science ®Google Scholar
• Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant 1993;11(1):75-6
   PubMed Web of Science ®Google Scholar
• Robin M, Guardiola P, Girinsky T, et al. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005;80(5):634-42
   PubMed Web of Science ®Google Scholar
• Devillier R, Castagna L, Gonzague L, et al. TLI in refractory chronic GVHD. Bone Marrow Transplant 2013;48(6):854-8
   PubMed Web of Science ®Google Scholar
• Chen YB, Cutler CS. Biomarkers for acute GVHD: can we predict the unpredictable? Bone Marrow Transplant 2013;48(6):755-60
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012;119(16):3854-60
   PubMed Web of Science ®Google Scholar
• Hilgendorf I, Mueller-Hilke B, Kundt G, et al. The lack of memory B cells including T cell independent IgM+ IgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. Transpl Int 2012;25(1):87-96
   PubMed Web of Science ®Google Scholar
• Kuzmina Z, Greinix HT, Weigl R, et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood 2011;117(7):2265-74
   PubMed Web of Science ®Google Scholar